Register online by Tuesday, September 29, 2020.
**Webinar log-in information will be sent out via email.
Disclaimer: The content does not necessarily reflect the views and opinions of Clinical TMS Society or its members and is solely determined by the sponsor.
The majority of time patients with bipolar disorder are ill, they are depressed. There are few FDA approved treatments for bipolar depression and all of them are second-generation antipsychotics which carry a high side effect burden. Clinical experience has suggested that TMS might be effective for bipolar depression. This presentation will review the existing literature on the efficacy of TMS for bipolar depression and present the findings from a two-center open-label prospective trial of TMS in bipolar depression including type I and type II patients.
At the end of the presentation, attendees will gain an understanding of the existing literature on the efficacy of TMS for bipolar depression and learn additional insights from an examination of a two-center open-label trial.
Presented by Scott Aaronson, M.D.
Dr. Scott Aaronson is director of clinical research programs, director of transcranial magnetic stimulation services, and chair of the medical executive committee at Sheppard Pratt Health System in Baltimore, Maryland. He is an Adjunct Professor in the Department of Psychiatry at the University of Maryland School of Medicine. Dr. Aaronson specializes in treatment-resistant affective disorders. He is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies, and is the principal investigator for multiple studies on the development of novel therapies for mood and anxiety disorders. Dr. Aaronson is a valued speaker and educator and frequently lectures both regionally and nationally on mood disorders, including the integration of biological and psychotherapies, complex mood disorders, psychoeducation, and the development of new therapies. Much of his research work and publications center on the development of various neurostimulation paradigms including Transcranial Magnetic Stimulation, Vagus Nerve Stimulation, Direct Current Stimulation, and synchronized TMS to treat severe mood disorders. Recently, he has begun research into the use of psychedelics in mood disorders including three studies looking at psilocybin in various presentations of depression. He is a member of the board of directors of the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr Aaronson earned his MD with honors from Harvard Medical School. He completed a residency in psychiatry at McLean Hospital, as well as a fellowship in sleep physiology at Harvard Medical School. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists.
NeuroStar® Advanced Therapy System Clinical Outcomes Registry has documented treatment parameters and clinical outcomes in over 9,000 unique individuals treated at over 100 private practice sites in the US. This presentation reports new findings regarding the efficacy of TMS in adult patients treated for an episode of major depressive disorder in community settings. Demographic and treatment parameter correlates of treatment outcomes will be examined. New findings will also be presented regarding the relative efficacy of the Standard NeuroStar protocol (inter-train interval of 26 s; 38-minute session) and the Dash protocol (inter-train interval of 11 s; 19-minute session).
At the end of the presentation, attendees will gain insights into the real-world treatment outcomes of MDD and the efficacy of TMS leveraging the largest clinical data set in MDD.
Presented by Harold A. Sackeim, Ph.D.
Dr. Harold A. Sackeim is Professor of Clinical Psychology in Psychiatry and Radiology, College of Physicians and Surgeons, Columbia University. He served as Chief of the Department of Biological Psychiatry at the New York State Psychiatric Institute for 25 years. He is also the Founding Editor of the journal, Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation. He received his first B.A. from Columbia College, Columbia University (1972), another B.A. and an M.A. from Magdalen College, Oxford University (1974) and his Ph.D. from the University of Pennsylvania (1977), where he also completed his clinical training in the Department of Psychiatry. He joined the faculty of Columbia University in 1977, where he remains today.